- Within the placebo group, there was no statistically significant reduction in the number of days with any GI-related symptoms*9
*Results are from a 6-week, randomized, double-blind, placebo-controlled study in which 66 male and female patients were assigned to receive
10 g per day of EnteraGam™ (n=25), 5 g per day of EnteraGam™ (n=19), or placebo (n=22). The study was not powered to demonstrate between-group differences. GI symptoms were recorded by study subjects in a daily diary assessing the presence and severity of symptoms on a scale of 0 to 3
(0 = none, 1 = mild, 2 = moderate, 3 = severe). The number of days with symptoms was calculated for each 2-week period for each subject. Data
above represent the within-group changes from baseline to end of treatment among the 15 patients taking 10 g per day of EnteraGam™ who
completed the study. Withdrawal rates were similar across groups.9 (Note: The recommended dosing range of EnteraGam™ is 5 g to 20 g per day.)
10 g per day of EnteraGam™ (n=25), 5 g per day of EnteraGam™ (n=19), or placebo (n=22). The study was not powered to demonstrate between-group differences. GI symptoms were recorded by study subjects in a daily diary assessing the presence and severity of symptoms on a scale of 0 to 3
(0 = none, 1 = mild, 2 = moderate, 3 = severe). The number of days with symptoms was calculated for each 2-week period for each subject. Data
above represent the within-group changes from baseline to end of treatment among the 15 patients taking 10 g per day of EnteraGam™ who
completed the study. Withdrawal rates were similar across groups.9 (Note: The recommended dosing range of EnteraGam™ is 5 g to 20 g per day.)
Please see full Important Safety Information in Safety section and
full Prescribing Information including contraindications in PI section.
full Prescribing Information including contraindications in PI section.